Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial
- Journal:
- Nature Communications
- Published:
- Affiliations:
- 7
- Authors:
- 19
| Institutions | Authors | Share |
|---|---|---|
| The University of Hong Kong (HKU), China | 0.75 | |
| Centre for Oncology and Immunology, China | 0.21 | |
| Sun Yat-sen University (SYSU), China | 0.03 | |
| Li Ka Shing Faculty of Medicine, HKU, China | 0.02 |